Inventor · disambiguated record
Louis M. Weiner
Also filed as: WEINER LOUIS · WEINER LOUIS M
13 granted patents·6 pending applications·193 citations·filing 2003–2024
90Inventor score
Top patents by PatentIndex Score
19 records- 0195US8329873B2Bispecific single chain Fv antibody molecules and methods of use thereofADAMS GREGORY P·Filed 2007·Granted Dec 11, 2012·28 cites·17 claims
- 0295US7332580B2Bispecific single chain Fv antibody molecules and methods of use thereofUNIV CALIFORNIA·Filed 2003·Granted Feb 19, 2008·76 cites·9 claims
- 0393US7332585B2Bispecific single chain Fv antibody molecules and methods of use thereofCALIFORNIA UNIVERSITY·Filed 2005·Granted Feb 19, 2008·60 cites·13 claims
- 0491US8580263B2Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereofADAMS GREGORY P·Filed 2007·Granted Nov 12, 2013·20 cites·18 claims
- 0587US9567641B2Combination therapy for the treatment of cancer using an anti-C-met antibodySAMSUNG ELECTRONICS CO LTD·Filed 2014·Granted Feb 14, 2017·6 cites·6 claims
- 0682US11278551B2Treating cancer with a CCK receptor inhibitor and an immune checkpoint inhibitorUNIV GEORGETOWN·Filed 2018·Granted Mar 22, 2022·2 cites·29 claims
- 0775US2024216391A1Treating fibrosis with a cck receptor inhibitorUNIV GEORGETOWN·Filed 2024·Application pending·0 cites
- 0874US8980258B2Bispecific single chain Fv antibody molecules and methods of use therofUNIV CALIFORNIA·Filed 2012·Granted Mar 17, 2015·1 cites·21 claims
- 0973US12453735B2Treating cancer with a CCK receptor inhibitor and an immune checkpoint inhibitorUNIV GEORGETOWN·Filed 2022·Granted Oct 28, 2025·0 cites·6 claims
- 1058US9101631B2Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancerRATUSHNY VLADIMIR·Filed 2009·Granted Aug 11, 2015·0 cites·13 claims
- 1158US2024115670A1Fibroblast activation protein modulation to alter immune cell migration and tumor infiltrationUNIV GEORGETOWN·Filed 2022·Application pending·0 cites
- 1257US10450613B2EGFR/NEDD9/TGF-β interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disordersFOX CHASE CANCER CENTER·Filed 2016·Granted Oct 22, 2019·0 cites·2 claims
- 1357US9534050B2Antibodies to tumor endothelial marker 7RCANCER RES INST·Filed 2014·Granted Jan 3, 2017·0 cites·24 claims
- 1453US2013331294A1Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disordersFOX CHASE CANCER CT·Filed 2013·Application pending·0 cites
- 1550US2020319163A1Methods and compositions overcoming cancer cell immune resistanceUNIV GEORGETOWN·Filed 2020·Application pending·0 cites
- 1648US2011033461A1Combination Therapy for the Treatment of CancerRATUSHNY VLADIMIR·Filed 2009·Application pending·0 cites
- 1742US9677072B2Methods of inhibiting proliferation of estrogen-independent cancer cellsWEINER LOUIS M·Filed 2012·Granted Jun 13, 2017·0 cites·3 claims
- 1842US8883978B2Antibodies to tumor endothelial marker 7RBORGHAEI HOSSEIN·Filed 2011·Granted Nov 11, 2014·0 cites·18 claims
- 1938US2010239656A1Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disordersASTSATUROV IGOR·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →